Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
Cooley advised Angion on the deal. Angion, a clinical-stage biopharmaceutical company, announced its definitive merger agreement with Elicio Therapeutics. Elicio will merge with a wholly owned subsidiary...
You must be a Standard 1 Year member to access this content.
Cooley advised HOF Capital on the deal. HOF Capital, a multistage venture capital firm that invests in ambitious entrepreneurs, announced its $300 million latest early-stage fund....
You must be a Standard 1 Year member to access this content.
Cooley advised Intersect ENT on the deal, while Ropes & Gray advised Medtronic. Intersect ENT, a global ear, nose and throat medical technology leader dedicated to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Inspirato on the deal. Simpson Thacher advised UBS Securities LLC, Evercore Group L.L.C., and Stifel, Nicolaus & Company on the...
You must be a Standard 1 Year member to access this content.
